<DOC>
	<DOC>NCT02171390</DOC>
	<brief_summary>The study searched for answers to two questions 1. Is there endothelial dysfunction, inflammation and insulin resistance in patients with congenital hypogonadotropic hypogonadism? 2. What is the effect of testosterone replacement therapy on endothelial dysfunction, inflammation and insulin resistance?</brief_summary>
	<brief_title>Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Men Treatment naive Hypogonadotrophic hypogonadism Previous history of androgen replacement Chronic metabolic disorders</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Endothelial dysfunction</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Testosterone replacement therapy</keyword>
</DOC>